Ipca Laboratories Reports Consolidated Growth, Drives Margin Improvement in Q4 FY26
Ipca Laboratories Ltd has reported consolidated growth and significant margin improvements for the fourth quarter of fiscal year 2025-2026 (Q4 FY26), alongside strong performance indicators across its major business segments. The company's overall business size continued to grow, supported by robust growth in generic and promotional branded export businesses.The consolidated business grew by approximately 6% to stand at around INR1,396 crores, up from INR1,266 crores in the previous financial year (FY26). For the full fiscal year March 2026, the consolidated revenue saw an increase of about 8%, reaching INR9,646 crores compared to INR8,940 crores...